Nyxoah SA
Nyxoah SA is a medical technology company focused on neuromodulation-based treatments for obstructive sleep apnea. Its core product is the Genio system, an implantable therapy designed for patients with moderate to severe OSA, and the company operates from Belgium with commercial reach in the United States and multiple international markets.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueGenio-based neuromodulation systems used to treat obstructive sleep apnea.
Sales of implanted systems and related components to treatment centers and hospitals.
Support services tied to device adoption, physician training, and center onboarding.
Customers
Nyxoah sells into hospitals, ambulatory surgery centers, and specialist sleep/ENT practices that implant and manage treatment for obstructive sleep apnea patients. The buying decision is driven by clinical fit, reimbursement access, physician training, and the ability to offer an alternative to existing OSA therapies.
Buy Genio systems and use them to deliver implant-based OSA therapy.
Adopt and recommend the therapy because it expands treatment options for OSA patients.
Do not buy the product directly, but determine whether centers can routinely use it.
Support commercialization in markets where Nyxoah uses partner-led sales.
Strategy
Nyxoah’s strategy centers on building a clinical ecosystem around Genio, expanding reimbursement coverage, and widening the installed base of implanting centers. The company is also scaling manufacturing and commercialization capacity to support U.S. growth and broader international adoption while preserving product and clinical credibility.
The U.S. is a major market for OSA devices and requires training, adoption, and reimbursement support.
Coverage decisions determine whether therapy can be used routinely and at scale.
Higher capacity is needed to meet demand and support a broader international footprint.
Post-approval studies and clinical outcomes support physician adoption and payer confidence.
Geography
Nyxoah is headquartered in Belgium and has manufacturing, product development, and commercialization activities tied to Europe and the United States. The company has disclosed revenue and market entry across the U.S., Switzerland, the U.K., the Netherlands, the Middle East, and several other European markets, which makes reimbursement and regulatory access central to its geography profile.
Risks
Nyxoah’s business depends on regulatory approvals, reimbursement decisions, and successful physician adoption of a relatively specialized implantable therapy. The company also faces execution risk as it scales manufacturing and commercialization across multiple geographies, while demand can vary by country-specific coverage and clinical practice patterns.
- Reimbursement dependencyImpact: HighLikelihood: High
OSA implant adoption is highly sensitive to payer coverage and national reimbursement pathways.
Exposure - Regulatory executionImpact: HighLikelihood: Medium
The product must maintain approvals and satisfy post-approval clinical requirements.
Exposure: U.S. PMA pathway and international approvals
- Commercial adoption riskImpact: MediumLikelihood: High
Physician training and center conversion are needed before recurring use can build.
Exposure: U.S. implant centers and European specialists
- Manufacturing and supply chain executionImpact: MediumLikelihood: Medium
Device supply must scale reliably while preserving quality and regulatory compliance.
Exposure: Belgium and U.S. manufacturing footprint
- Clinical evidence riskImpact: MediumLikelihood: Medium
Future study results can influence treatment positioning and market acceptance.
Exposure: BREATHE post-PMA study and broader evidence base
Accounting
Judgemental itemsEarly commercialization can create uneven recognition as systems ship to new centers.
Impact: Affects quarterly comparability and launch-period revenue patterns
The company excludes certain capitalized R&D from non-GAAP cash operating expenses.
Impact: Affects operating expense presentation and cash burn analysis
Post-approval studies such as BREATHE can create sizable period costs and accrual estimates.
Impact: Affects research expense and liability accruals
Medical device companies must test whether acquired or developed intangibles remain recoverable.
Impact: Can create non-cash charges if assumptions weaken
Similar listed companies
Publicly listed companies with a comparable business focus.
Apnimed, Inc.
APMD · Pharmaceutical Preparations
Inspire Medical Systems, Inc.
INSP · Surgical & Medical Instruments & Apparatus
Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea.
RemSleep Holdings Inc.
RMSL · Services-Personal Services
Zynex Inc
ZYXIQ · Electromedical & Electrotherapeutic Apparatus
Vivos Therapeutics, Inc.
VVOS · Surgical & Medical Instruments & Apparatus
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Last updated: 28/09/2026